8-KThe WireRoutine
Shareholder Vote
Filed May 10, 2023 · 3y ago · Accession 0001104659-23-058520
Plain English
Material event — a significant development the company must disclose promptly.
Read the source below for the full document.
Filing text
View original ↗UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington , D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 5, 2023
ABBVIE
INC.
(Exact name of registrant as specified in its charter)
Delaware
001-35565
32-0375147
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
1 North Waukegan Road
North Chicago , Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: ( 847 ) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, $0.01 Par Value
ABBV
New
York Stock Exchange
Chicago
Stock Exchange
1.500%
Senior Notes due 2023
ABBV23B
New
York Stock Exchange
1.375%
Senior Notes due 2024
ABBV24
New
York Stock Exchange
1.250%
Senior Notes due 2024
ABBV24B
New
York Stock Exchange
0.750%
Senior Notes due 2027
ABBV27
New
York Stock Exchange
2.125%
Senior Notes due 2028
ABBV28
New
York Stock Exchange
2.625%
Senior Notes due 2028
ABBV28B
New
York Stock Exchange
2.125%
Senior Notes due 2029
ABBV29
New
York Stock Exchange
1.250%
Senior Notes due 2031
ABBV31
New
York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value
ABBV
Item
5.07 Submission
of Matters to a Vote of Security Holders.
AbbVie
Inc. (“AbbVie”) held its Annual Meeting of Stockholders on May 5, 2023. The following is a summary of the matters voted
on at that meeting.
(1)
The
stockholders elected AbbVie’s Class II Directors with terms expiring in 2026, as follows:
Name
For
Against
Broker
Non-Votes
Robert
J. Alpern
1,142,062,843
20,689,813
251,363,568
Melody
B. Meyer
1,247,333,998
4,243,832
251,363,568
Frederick
H. Waddell
1,208,836,612
14,319,844
251,363,568
(2)
The
stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm
for 2023, as follows:
For
Against
Abstain
1,486,053,290
18,676,821
3,224,042
(3)
The
stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers listed in the proxy statement
for the 2023 annual meeting, as follows:
For
Against
Abstain
Broker
Non-Votes
1,137,389,680
109,281,658
9,919,247
251,363,568
(4)
The
stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority
voting, as follows:
For
Against
Abstain
Broker
Non-Votes
1,241,106,832
11,289,016
4,194,737
251,363,568
(5)
The
stockholders approved a stockholder proposal to implement simple majority voting, as follows:
For
Against
Abstain
Broker
Non-Votes
668,497,335
581,300,391
6,792,859
251,363,568
(6)
The
stockholders did not approve a stockholder proposal to issue an annual report on political spending, as follows:
For
Against
Abstain
Broker
Non-Votes
187,829,409
1,052,110,624
16,650,552
251,363,568
(7)
The
stockholders did not approve a stockholder proposal to issue an annual report on lobbying, as follows:
For
Against
Abstain
Broker
Non-Votes
448,957,091
787,145,991
20,487,503
251,363,568
(8)
The
stockholders did not approve a stockholder proposal to issue an annual report on patent process, as follows:
For
Against
Abstain
Broker
Non-Votes
363,777,601
867,061,281
25,751,703
251,363,568
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
ABBVIE
INC.
Date:
May 10,
2023
By:
/s/
Perry C. Siatis
Perry
C. Siatis
Executive
Vice President, General Counsel and Corporate Secretary
Filing details
- Company
- AbbVie Inc.
- Ticker
- ABBV
- CIK
- 1551152
- Form type
- 8-K
- Filing date
- May 10, 2023
- Report date
- May 5, 2023
- Document
- tm2315162d1_8k.htm
- Size
- 353 KB